靶向B7-H3的CAR-T细胞在实体瘤免疫治疗的研究进展

Progress in B7-H3 targeted CAR-T cells for immunotherapy of solid tumors

近年,以嵌合抗原受体修饰T细胞(CAR-T)为代表的过继细胞免疫疗法在血液系统肿瘤中的治疗取得了突破性进展。然而对于实体瘤的治疗,CAR-T疗法仍面临着一系列挑战。肿瘤异质性、T细胞归巢效率低下、肿瘤免疫抑制性微环境和特异性抗原的缺乏是限制CAR-T在实体瘤中发挥作用的重要因素。B7-H3是B7免疫球蛋白超家族成员,在多种实体瘤中高表达,作为肿瘤免疫治疗的分子靶点受到广泛关注。本文总结了B7-H3的分子特点及其在肿瘤中的功能,并对以B7-H3为靶点的CAR-T疗法在实体瘤中的研究进展做一综述。

In recent years,significant progresses have been made in adoptive cell therapy with chimeric antigen receptor-T cells(CAR-T)for hematological malignancies.However,the treatment of solid tumors still poses a tremendous challenges.Several factors are held responsible for the inadequate responses:tumor heterogeneity,inefficient homing of T cells,immunosuppressive microenvironment and lack of specific antigens.B7-H3 is a member of the B7 immunoglobulin superfamily and highly expressed in various solid tumors.As such,it has attracted much attention as a molecular target in cancer immunotherapy.In this review,we summarizes the molecular characteristics of B7-H3 and its functions in tumors,and focus on the research progress of CAR-T cells directed against B7-H3 for solid tumors.